The protein arginine methyltransferase (PRMT) family catalyzes protein arginine methylation. Many cancers link to dysregulation of protein arginine methylation, making PRMTs an important target for anti-cancer treatments. PRMT4 is a type I PRMT that catalyzes asymmetric dimethylarginine and monomethylarginine. It is a coactivator for several nuclear receptors and transcription factors. (Du et al, 2021)
PRMT4 is important for many cellular processes, including transcription activation, RNA processing, tumorigenesis & cancer progression, cell growth/differentiation, and apoptosis. Breast cancer, lung cancer, colorectal cancer, and prostate cancer have all linked to PRMT4 mutations. (Du et al, 2021)
The AptaFluor PRMT4 Assay is a powerful tool to screen compound libraries for PRMT4 modulators to help find new therapies for disease.